Dr. Sagel is a pediatrician who focuses on airway inflammation and lung disease in children with cystic fibrosis and primary ciliary dyskinesia. He serves as the director of the University of Colorado Cystic Fibrosis Center, as well as the lead site investigator for the National Institute of Health-funded Genetic Disorders of Mucociliary Clearance Consortium, a network dedicated to improving diagnostics and treatments for individuals with primary ciliary dyskinesia.
Dr. Sagel’s research interests include: biomarkers of lung disease, including sputum and systemic markers of airway inflammation and injury; airway infections in cystic fibrosis including nontuberculous mycobacteria and the microbiome; and how bacterial pathogens relate to clinical outcomes in cystic fibrosis. Dr. Sagel’s research has been supported by the National Institutes of Health and the Cystic Fibrosis Foundation (CFF).
An active member of the CFF, Dr. Sagel serves as co-chair of the CFF Biomarker Consortium and former chair of the Therapeutics Development Network Inflammatory Biomarkers Working Group.
Dr. Sagel is Director of the NIH-funded University of Colorado Pediatric Clinical Translational Research Center Core Laboratory based at Children's Hospital Colorado and Director of the CFF-funded Center for Biochemical Markers.